Neurocrine Biosciences Inc (NBIX)
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Neurocrine Biosciences Inc is a Healthcare company with a market capitalization of $16.94B and a trailing P/E ratio of 25.9.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $1.94 | $1.70 | +14.1% |
| Q4 2025 | February 11, 2026 | $1.88 | $2.30 | -18.3% |
| Q3 2025 | October 28, 2025 | $2.17 | $2.07 | +4.8% |
| Q2 2025 | July 30, 2025 | $1.06 | $0.99 | +7.1% |
| Q1 2025 | May 5, 2025 | $0.70 | $1.09 | -35.8% |
| Q4 2024 | February 6, 2025 | $1.69 | $1.93 | -12.4% |
Other Drug Manufacturers - Specialty & Generic Stocks
Frequently Asked Questions
What is Neurocrine Biosciences Inc's market cap?
As of June 29, 2026, Neurocrine Biosciences Inc (NBIX) has a market capitalization of $16.94B.
What is Neurocrine Biosciences Inc's P/E ratio?
Neurocrine Biosciences Inc trades at a trailing price-to-earnings (P/E) ratio of 25.9. Its forward P/E is 23.2.
Does Neurocrine Biosciences Inc pay a dividend?
Neurocrine Biosciences Inc does not currently pay a dividend.
What sector is NBIX in?
Neurocrine Biosciences Inc is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
What was Neurocrine Biosciences Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Neurocrine Biosciences Inc reported revenue of $2.86B and net income of $478.60M.
Ask your own questions about NBIX
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.